Therapeutic Candidate definition

Therapeutic Candidate means the plasmid, known as SB-509, that encodes a zinc finger DNA-binding protein designed to upregulate the expression of vascular endothelial growth factor (VEGF-A).
Sample 1Sample 2Sample 3
Therapeutic Candidate means a peptide, protein or Genetic Material discovered, identified, produced or tested during the Research Period pursuant to the Research, or identified during the Tail End Period, which meets the Success Criteria, and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or its homologues or derivatives) shall be within the definition of Therapeutic Candidate (and vice-versa).
Sample 1Sample 2Sample 3
Therapeutic Candidate means a peptide, protein or Genetic Material discovered, identified, produced or tested during the Research Period pursuant to the Research (whether pursuant to this Agreement or pursuant to the Novartis Angiogenesis Collaboration), or identified during the Tail End Period, by either Party, which meets the Success Criteria, and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or homologues or derivatives of such Genetic Material) shall be within the definition of Therapeutic Candidate (and vice-versa). The rights of the Parties with respect to Therapeutic Candidates that are also Targets are as set forth in Section 2.4.
Sample 1Sample 2

Examples of Therapeutic Candidate in a sentence

  • It is understood and agreed that the licenses granted above in this Section 2.1(b) shall specifically exclude the right to make or use any Target or Therapeutic Candidate as a therapeutic agent or for purposes relating to delivery of a Target or Therapeutic Candidate via Gene Therapy.

  • The RMC shall evaluate the results of the Research set forth in the research reports pursuant to Section 3.4(a) to assess whether a peptide, protein or Genetic Material is a Therapeutic Candidate, and perform such other duties as specifically delegated to the RMC by mutual written agreement of the Parties.

  • At any time following completion of in vivo studies conducted with a Therapeutic Candidate pursuant to a Co-Development Plan, unless earlier agreed upon by the "Parties", the "Parties" may, if both agree in writing, out license to one or more Third "Parties" any or all of the development and commercialization rights to any Therapeutic Product.

  • In Sole Development, (i) the Developing party shall be solely responsible for all remaining expenses incurred in connection with the ongoing development and commercialization of such Therapeutic Candidate, as described in Section 5.1.3, and (ii) the Financial Interests of the "Parties" shall be as described in Section 5.2.2.

  • Sangamo will use Commercially Reasonable Efforts to identify [*] Therapeutic Candidates and [*] Therapeutic Candidate that [*] set forth in the applicable Research Plan.

  • In consideration for its completion of a Research Project and equal financial participation in a Co-Development Program, each party shall be entitled to a 50% Financial or otherwise Interest in any Therapeutic Candidate; provided that, the "Parties" have entered into a Co-Development Agreement to develop a Therapeutic Diagnostic or Life Science Reagent Candidate.

  • The license granted to Epitomics under this section shall be: (i) an exclusive license in Sole Development, except to the extent that it is granted to Epitomics in connection with the Co-Development of a Therapeutic Candidate, Diagnostic or Life Science Reagent in with case it shall be a co-exclusive license (with InNexus), for the life of InNexus Patent Rights; and (ii) subject to the financial obligations set forth in Article 5.

  • The Developing Party shall use commercially reasonable efforts to diligently perform its obligations under this Article 4 and to develop and commercialize the Therapeutic Candidate in the Field of Use.

  • The license granted to InNexus under this section shall be: (i) an exclusive license in Sole Development, except to the extent that it is granted to InNexus in, connection with the Co-Development of a Therapeutic Candidate, Diagnostic or Life Science reagent, in with ease it shall be a co-exclusive license (with EPITOMICS), for the life of EPITOMICS Patent Rights; and (ii) subject to the financial obligations set forth in Article 5, 6.1.2License to TransMAb Antibody.

  • Subject to the terms and conditions of this Agreement, Biogen shall have sole control over and decision-making authority with respect to all regulatory activities related to obtaining and maintaining Regulatory Approval and Pricing Approval for the Products in the Field in the Territory, at its own cost and expense, including all communications with any Regulatory Authorities and submissions thereto, in each case, regarding any Therapeutic Candidate or Product.


More Definitions of Therapeutic Candidate

Therapeutic Candidate means any ZFP-containing molecule (including a Zinc Finger Nuclease or Zinc Finger Transcription Factor) that (a) [*] to a Collaboration Target, (b) is the subject of Sangamo Research Activities under the applicable Research Plan and (c) [*] under the applicable Research Plan. 1.208 “Therapeutic Field” means the treatment or prevention of disease in humans or animals in any and all indications. 1.209 “Third Party” means any Person other than a Party or an Affiliate of a Party. 1.210 “Third Party Distributor” means, with respect to a Product in any country, any Third Party that purchases its requirements for such Product in such country from Biogen or its Affiliates or Sublicensees and is appointed by Biogen or its Affiliate or Sublicensee as a distributor to distribute, market and resell such Product in such country, even if such Third Party is granted ancillary rights to Develop, package or obtain Regulatory Approval for such Product in order to distribute, market or sell such Product in such country. 1.211 “Trademarks” means all trademarks, service marks, trade names, service names, internet domain names, brand names, logos, protectable slogans and trade dress rights, whether registered or unregistered, and all applications, registrations and renewals thereof. 1.212 “Transition Plan” has the meaning set forth in Section 12.5(b) (Transition to Sangamo). 1.213 “Unauthorized Inventing Party” has the meaning set forth in Section 10.1(d) (Unauthorized Inventions). 1.214 “Unauthorized Inventions” has the meaning set forth in Section 10.1(d) (Unauthorized Inventions). 1.215 “United States” or “U.S.” means the United States of America, including its territories and possessions. 1.216 “Upfront Payment” has the meaning set forth in Section 9.1 (Upfront Payment). 1.217 “Upstream License” means any agreement between Sangamo (or any of its Affiliates) and any Third Party (such Third Party, an “Upstream Licensor”) under which such Third Party grants Sangamo a license under any of the Licensed Technology, but expressly 24 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Sample 1
Therapeutic Candidate means any TransMab Antibody selected for Co-Development by the "parties" in accordance with Section 2.5.1.
Sample 1
Therapeutic Candidate means a peptide, protein or Genetic Material discovered, identified, produced or tested during the Research Period pursuant to the Research (whether pursuant to this Agreement or pursuant to the Novartis Angiogenesis Collaboration), or identified during the Tail End Period, by either Party, which meets the Success Criteria, and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or homologues or derivatives of such Genetic Material) shall be within the definition of Therapeutic Candidate (and vice- versa). The rights of the Parties with respect to Therapeutic Candidates that are also Targets are as set forth in Section 2.4.
Sample 1
Therapeutic Candidate means a peptide, protein or Genetic Material discovered, identified, produced or tested during the Research Period pursuant to the Research [*], or identified during the Tail End Period, by either Party, which meets the Success Criteria, and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or homologues or derivatives of such Genetic Material) shall be within the definition of Therapeutic Candidate (and vice-versa). The rights of the Parties with respect to Therapeutic Candidates that are also Targets are as set forth in Section 2.4.
Sample 1

Related to Therapeutic Candidate

  • Therapeutic diet means meals served that are soft, low-fat, low-sodium or controlled calorie.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Therapeutic Product means a health product categorised as a therapeutic product in the First Schedule to the Act;

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • Licensed Compound means [***].

  • Therapeutic school means a residential group living facility:

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Antibody means a molecule comprising or containing one or more immunoglobulin variable domains or any fragments, derivatives, variants or modifications thereof that bind to the same antigen.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Therapeutic care means services provided by licensed or certified speech pathologists, Occupational Therapists and Physical Therapists.

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Therapeutic equivalent means that a Covered Drug can be expected to produce essentially the same therapeutic outcome and toxicity.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Biosimilar Product means, with respect to a Licensed Product and on a country-by-country basis, a product that [***].

  • Active Pharmaceutical Ingredient or “API” shall mean one or more of the following active pharmaceutical ingredients: tenofovir alafenamide (“TAF”), tenofovir disoproxil fumarate (“TDF”), elvitegravir (“EVG”), and cobicistat (“COBI”).

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Opioid antagonist means a drug that binds to opioid

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Reference biological product means the single biological product licensed pursuant to 42 U.S.C.

  • Pivotal Clinical Trial means a human clinical trial in any country that is prospectively designed to generate data intended to satisfy the requirements of 21 C.F.R. § 312.21(c) (as amended) in the U.S. or a similar clinical study prescribed by a Regulatory Authority from another country, from time to time, pursuant to Applicable Law.

  • Compound means the taking of two or more ingredients and fabricating them into a single